← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #458 OF 1,000 MOST-CITED

DHR - UDI not included

FDA cited this observation 41 times across 41 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Devices41
BY FISCAL YEAR
FY20261
FY20253
FY202310
FY20225
FY20206
FY201915
FY20181

How FDA worded it — real examples

The device history record does not include, or refer to the location of any unique device identifier (UDI) or universal product code (UPC).

Amphenol DC Electronics Inc. · San Jose, California · Devices · 2025-10-23

The device history record does not include, or refer to the location of any unique device identifier (UDI) or universal product code (UPC).

Sheffield Pharmaceuticals, LLC · New London, Connecticut · Devices · 2025-06-18

The device history record does not include, or refer to the location of any unique device identifier (UDI) or universal product code (UPC).

Bio-Med Devices, Inc. · Guilford, Connecticut · Devices · 2024-12-20

The device history record does not include, or refer to the location of any unique device identifier (UDI) or universal product code (UPC).

Glottal Enterprises Inc. · Syracuse, New York · Devices · 2024-10-17

The device history record does not include, or refer to the location of any unique device identifier (UDI) or universal product code (UPC).

ACI Medical LLC · San Marcos, California · Devices · 2023-08-17

The device history record does not include, or refer to the location of any unique device identifier (UDI) or universal product code (UPC).

Blood Bank Computer Systems, Inc. · Bonney Lake, Washington · Devices · 2023-06-30

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Medical devices

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →